Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2021 | ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the pipeline of Atara Biotherapeutics including the ATA3219, an anti-CD19 allogeneic T-cell immunotherapy targeting B-cell malignancies, as well as ATA3271, a chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin for solid tumors. He additionally discusses the latest results from the Phase I/II EMBOLD study (NCT03283826) of ATA188, a T-cell immunotherapy that targets Epstein-Barr virus (EBV) in patients with progressive multiple sclerosis. This interview took place at Meeting on the Mesa 2021.


Pascal Touchon is the Chief Executive Officer of Atara Biotherapeutics, San Francisco, CA and a Board Member of Dantari Pharmaceuticals, Thousand Oaks, CA